Differences in Lipid Measurements by Antiretroviral Regimen Exposure in Cohorts from Asia and Australia
Open Access
- 14 May 2012
- journal article
- research article
- Published by Hindawi Limited in AIDS Research and Treatment
- Vol. 2012, 1-9
Abstract
We explored the mean differences in routinely measured lipids (total cholesterol, triglycerides, and high-density lipoprotein cholesterol) according to exposure to different combination antiretroviral regimens in Asian () and Australian (predominantly Caucasian,) cohorts. The regimen was defined as at least 3 antiretroviral drugs with at least 2 nucleoside-reverse transcriptases (NRTIs) and either of at least one protease inhibitor (PI) or non-nucleoside-reverse transcriptases (NNRTIs). We categorised cART regimens as: NRTIs as tenofovir based or not; NNRTIs as nevirapine or efavirenz (but not both); and PI as atazanavir based or not. We found that the impact of various antiretroviral regimens on lipids in Asian and Australian cohorts was only different by cohort for total cholesterol (for interaction between regimen and cohort: 0.05). The differences in total cholesterol were however small and unlikely to be of clinical significance. Overall, tenofovir with nevirapine or atazanavir was associated with the most favorable lipids, while the PI regimens without tenofovir and atazanavir were associated with least favorable lipids. We conclude that the impact of various ART regimens on lipids is largely similar in Asian and Australian cohorts and that the newer drugs such as tenofovir and atazanavir are likely to provide similar benefit in terms of lipid profiles in both populations.
Keywords
This publication has 21 references indexed in Scilit:
- The Clinical Significance of CD4 Counts in Asian and Caucasian HIV-Infected Populations: Results from TAHOD and AHODJournal of the International Association of Physicians in AIDS Care, 2011
- Dyslipidemia among HIV-infected Patients with Tuberculosis Taking Once-daily Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in IndiaClinical Infectious Diseases, 2011
- Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical careAIDS, 2011
- Effects of First-Line Use of Nucleoside Analogues, Efavirenz, and Ritonavir-Boosted Protease Inhibitors on Lipid LevelsHIV Research & Clinical Practice, 2009
- Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected PatientsCirculation, 2008
- Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studiesCurrent Opinion in HIV and AIDS, 2007
- Dyslipidemia in an Asian Population After Treatment for Two Years With Protease Inhibitor-Containing RegimensJournal of the International Association of Physicians in AIDS Care, 2007
- Associations among Race/Ethnicity, ApoC-III Genotypes, and Lipids in HIV-1-Infected Individuals on Antiretroviral TherapyPLOS Medicine, 2006
- Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1PLOS Medicine, 2004
- Some factors influencing serum lipid levels in a working populationAtherosclerosis, 1980